2 FDA observations leave EBR facility approval pending
EBR Systems has completed the FDA’s pre-approval inspection of its new Santa Clara manufacturing facility, receiving two Form 483 observations. The company says it expects to correct them in the fourth quarter and still anticipates approval by year-end, although the FDA has not yet made its final determination.
- FDA inspection completed at Santa Clara facility
- Two Form 483 observations issued
- EBR promised to correct both observations
- Final inspection classification and PMA decision remain pending
- Year-end 2026 approval expectation maintained
FDA Inspection Produces Two Observations
EBR Systems, Inc. (ASX:EBR) has cleared a key procedural hurdle for its new Santa Clara manufacturing facility, but the site is not approved yet. The U.S. Food and Drug Administration completed its pre-approval inspection as part of EBR’s application to add the facility as a manufacturing site for the WiSE System.
The investigator issued a Form FDA 483 listing two observations. EBR selected “Promised to Correct” for both, a response recorded on the inspection form. The company has not disclosed the substance of the observations, while President and Chief Executive Officer John McCutcheon described them as minor and said EBR expects to address them during the fourth quarter.
PMA Supplement Decision Still Ahead
A Form 483 is not the FDA’s final ruling on the facility or the company’s PMA supplement. The FDA’s Center for Devices and Radiological Health will review the inspection record before determining the final inspection classification and deciding the application to add the Santa Clara site.
EBR continues to anticipate approval by the end of 2026. That remains management’s expectation rather than a regulatory outcome, and the two observations create a follow-up step before the facility can be treated as an approved WiSE manufacturing site.
Manufacturing Scale-Up Awaits Clearance
The Santa Clara facility is intended to support EBR’s manufacturing scale-up and broader US commercial execution plans. The company said the site had already achieved ISO 13485 certification earlier in September, while new equipment had been installed to move certain manual production processes towards automated assembly.
The immediate question is whether EBR’s promised corrections satisfy the FDA without requiring further work that affects the approval timetable. Until the agency completes its review and grants the PMA supplement, the operational benefits of the new site remain prospective.
Bottom Line?
The inspection is complete, but the investment-relevant milestone is still the FDA’s final classification and PMA decision before year-end.
Questions in the middle?
- What do the two Form 483 observations require EBR to correct?
- Will the FDA’s final inspection classification support approval of the Santa Clara site by year-end?
- When approved, how quickly can the facility contribute to WiSE manufacturing scale-up and US commercial execution?
